Abstract

Acute ischemic stroke triggers complex systemic pathological responses for which the exploration of drug resources remains a challenge. Wasp venom extracted from Vespa magnifica (Smith, 1852) is most commonly used to treat rheumatoid arthritis as well as neurological disorders. Vespakinin-M (VK), a natural peptide from wasp venom, has remained largely unexplored for stroke. Herein, we first confirmed the structure, stability, toxicity and distribution of VK as well as its penetration into the blood–brain barrier. VK (150 and 300 µg/kg, i.p.) was administered to improve stroke constructed by middle cerebral artery occlusion in mice. Our results indicate that VK promote functional recovery in mice after ischemia stroke, including an improvement of neurological impairment, reduction of infarct volume, maintenance of blood-brain barrier integrity, and an obstruction of the inflammatory response and oxidative stress. In addition, VK treatment led to reduced neuroinflammation and apoptosis associated with the activation of PI3K–AKT and inhibition of IκBα–NF-κB signaling pathways. Simultaneously, we confirmed that VK can combine with bradykinin receptor 2 (B2R) as detected by molecular docking, the B2R antagonist HOE140 could counteract the neuro-protective effects of VK on stroke in mice. Overall, targeting the VK–B2R interaction can be considered as a practical strategy for stroke therapy.

Highlights

  • Acute ischemic stroke triggers complex systemic pathological responses for which the exploration of drug resources remains a challenge

  • adenosine diphosphate (ADP)-induced platelet aggregation was decreased in VK groups as compared to the control group, detailed values are shown in Supplementary Fig. 2a

  • According to the Stroke Therapy Academic Industry Roundtable (STAIR) recommendations[32], we investigated a dose-response experiment of VK treatment on stroke outcomes by middle cerebral artery occlusion/reperfusion (MCAO/R) in mice

Read more

Summary

Introduction

Acute ischemic stroke triggers complex systemic pathological responses for which the exploration of drug resources remains a challenge. The main therapeutic strategies[5] for AIS focus on restoring cerebral blood flow (CBF) and saving the ischemic penumbra by the administration of thrombolytic drugs such as intravenous recombinant tissue-type plasminogen activator[5,6,7,8]. Reperfusion by thrombolytic therapy after AIS can accelerate cerebral injury, resulting in brain edema, brain hemorrhage, and neuronal death. This phenomenon is termed as cerebral ischemia/reperfusion (I/ R) injury and is implicated in various types of cellular stress[10], including energy failure, oxidative stress, elevation of the intracellular Ca2+ levels, release of excitatory neurotransmitters, neuroinflammatory response, and apoptosis. Targeting the VK–B2R interaction can be considered a practical strategy for stroke therapy

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call